An engineer shows an experimental vaccine for the COVID-19 coronavirus that was tested at the Quality Control Laboratory at the Sinovac Biotech facilities in Beijing (Getty Images)
December 24, 2020 07:18 AM EST
Coronavirus

Covid-19 roundup: Sino­vac pulls back from a promised PhI­II da­ta re­veal, rais­ing ques­tions about ef­fi­ca­cy

John Carroll

Editor & Founder

Af­ter promis­ing to re­veal the da­ta on a piv­otal tri­al for Sino­vac’s Covid-19 vac­cine in Brazil, the au­thor­i­ties in­volved hit the pause but­ton on the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times